Drug intelligence / Profile preview

TEE886

Development stage: Unknown
Lead developer: Apteeus
Modality: Small Molecules

Overview

TEE886 is a small molecule therapeutic candidate being developed by Apteeus for the treatment of ACOX1 deficiency, a rare peroxisomal disorder also known as pseudoneonatal adrenoleukodystrophy. The condition is characterized by mutations in the ACOX1 gene, which leads to a deficiency in the enzyme acyl-CoA oxidase 1 and the subsequent toxic accumulation of very-long-chain fatty acids (VLCFAs). TEE886 is designed to target ACOX1 to address the underlying metabolic defect. As of late 2021, the program is in Phase 1 clinical development.

Targets

ACOX1 (Peroxisomal acyl-CoA oxidase 1)

Beyond the preview

Go deeper on TEE886.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TEE886.

Explore the full profile